APA-话题@MedSci

#APA#

153篇内容 | 3637人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338215, encodeId=cd941338215bb, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, objectType=article, longId=193965, objectId=a65b19396562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a65b19396562, replyNumber=0, likeNumber=84, createdTime=2020-05-13, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a65b19396562, moduleTitle=LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a65b19396562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338214, encodeId=e6f0133821446, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：Emapalumab治疗原发性噬血细胞性淋巴组织细胞增多症, objectType=article, longId=193715, objectId=511c193e15ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=511c193e15ce, replyNumber=0, likeNumber=61, createdTime=2020-05-09, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=511c193e15ce, moduleTitle=NEJM：Emapalumab治疗原发性噬血细胞性淋巴组织细胞增多症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=511c193e15ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338213, encodeId=191a13382134a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查, objectType=article, longId=192482, objectId=1c3c1924827f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c3c1924827f, replyNumber=0, likeNumber=86, createdTime=2020-04-20, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c3c1924827f, moduleTitle=再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c3c1924827f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338212, encodeId=6dce1338212ee, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Lancet Rheumato：Dapansutrile治疗痛风耀斑, objectType=article, longId=191806, objectId=d723191806eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d723191806eb, replyNumber=0, likeNumber=51, createdTime=2020-04-10, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d723191806eb, moduleTitle=Lancet Rheumato：Dapansutrile治疗痛风耀斑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d723191806eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338211, encodeId=08ee13382115c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=JAMA：Apabetone不能降低高危人群心血管事件风险, objectType=article, longId=191232, objectId=9acb191232be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb191232be, replyNumber=0, likeNumber=77, createdTime=2020-04-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb191232be, moduleTitle=JAMA：Apabetone不能降低高危人群心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb191232be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338210, encodeId=f822133821055, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=达格列净III期DAPA-CKD研究因在慢性肾脏病患者中的压倒性疗效而计划提前终止, objectType=article, longId=191213, objectId=325f19121325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=325f19121325, replyNumber=0, likeNumber=76, createdTime=2020-04-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=325f19121325, moduleTitle=达格列净III期DAPA-CKD研究因在慢性肾脏病患者中的压倒性疗效而计划提前终止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=325f19121325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338209, encodeId=36d81338209b2, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL 2020：乙型肝炎新药研发进展, objectType=article, longId=190117, objectId=926619011e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=926619011e18, replyNumber=0, likeNumber=58, createdTime=2020-03-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=926619011e18, moduleTitle=APASL 2020：乙型肝炎新药研发进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=926619011e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338208, encodeId=82b91338208bf, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2020 APAGE/APLAR/APSDE/APSH/APSN/PoA联合建议：高血压、心血管、肾脏或胃肠道共病患者应用非甾体类抗炎药治疗, objectType=article, longId=186657, objectId=063918665efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063918665efa, replyNumber=0, likeNumber=35, createdTime=2020-01-24, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063918665efa, moduleTitle=2020 APAGE/APLAR/APSDE/APSH/APSN/PoA联合建议：高血压、心血管、肾脏或胃肠道共病患者应用非甾体类抗炎药治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=063918665efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338207, encodeId=fe87133820e98, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=改良Sauve－Kapandji手术治疗陈旧性下尺桡关节脱位1例, objectType=article, longId=186308, objectId=4c6318630849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c6318630849, replyNumber=0, likeNumber=74, createdTime=2020-01-17, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c6318630849, moduleTitle=改良Sauve－Kapandji手术治疗陈旧性下尺桡关节脱位1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c6318630849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338206, encodeId=4078133820639, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, objectType=article, longId=185399, objectId=b7f018539947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7f018539947, replyNumber=0, likeNumber=0, createdTime=2019-12-30, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7f018539947, moduleTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7f018539947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338205, encodeId=9d5e13382059b, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：Niraparib一线治疗晚期卵巢癌, objectType=article, longId=184964, objectId=1d621849647a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d621849647a, replyNumber=0, likeNumber=67, createdTime=2019-12-21, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d621849647a, moduleTitle=NEJM：Niraparib一线治疗晚期卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d621849647a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338204, encodeId=3113133820429, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标, objectType=article, longId=184167, objectId=053a18416e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a18416e94, replyNumber=0, likeNumber=0, createdTime=2019-12-06, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a18416e94, moduleTitle=Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053a18416e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338203, encodeId=03c31338203e7, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：达格列净在射血分数降低心衰患者的疗效（DAPA-HF研究）, objectType=article, longId=183365, objectId=d34e183365f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d34e183365f1, replyNumber=0, likeNumber=93, createdTime=2019-11-23, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d34e183365f1, moduleTitle=NEJM：达格列净在射血分数降低心衰患者的疗效（DAPA-HF研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d34e183365f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338202, encodeId=4e9d133820214, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据, objectType=article, longId=183273, objectId=f3641832e38a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3641832e38a, replyNumber=0, likeNumber=73, createdTime=2019-11-21, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3641832e38a, moduleTitle=全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3641832e38a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338201, encodeId=2b8513382013c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=AHA 2019｜LBS.01 首发四个临床研究：DAPA-HF、ORION-10、COLCOT、 BETonMACE, objectType=article, longId=183114, objectId=fe5618311484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe5618311484, replyNumber=0, likeNumber=55, createdTime=2019-11-19, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe5618311484, moduleTitle=AHA 2019｜LBS.01 首发四个临床研究：DAPA-HF、ORION-10、COLCOT、 BETonMACE, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe5618311484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338200, encodeId=0f0f13382001e, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, objectType=article, longId=181868, objectId=ccf018186817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccf018186817, replyNumber=0, likeNumber=69, createdTime=2019-10-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccf018186817, moduleTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccf018186817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338199, encodeId=00b1133819990, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=93, createdTime=2019-10-07, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338198, encodeId=cee91338198a5, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=53, createdTime=2019-10-06, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338197, encodeId=02ae133819e9b, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=每周一次的somapacitan治疗生长激素缺乏症儿童，效果与每日一次的生长激素相当, objectType=article, longId=179928, objectId=4a451e992828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a451e992828, replyNumber=0, likeNumber=61, createdTime=2019-09-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a451e992828, moduleTitle=每周一次的somapacitan治疗生长激素缺乏症儿童，效果与每日一次的生长激素相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a451e992828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338196, encodeId=17fe133819604, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, objectType=article, longId=178809, objectId=55521e880970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55521e880970, replyNumber=0, likeNumber=70, createdTime=2019-09-06, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55521e880970, moduleTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55521e880970)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APA

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

LYNPARZA（olaparib）联合贝伐单抗一线治疗HRD阳性晚期卵巢癌：已获FDA首肯

2020-05-13

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：Emapalumab治疗原发性噬血细胞性淋巴组织细胞增多症

2020-05-09

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

再鼎医药的PARP抑制剂Niraparib用于卵巢癌维持治疗，获得NMPA授予优先审查

2020-04-20

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Lancet Rheumato：Dapansutrile治疗痛风耀斑

2020-04-10

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

JAMA：Apabetone不能降低高危人群心血管事件风险

2020-04-03

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

达格列净III期DAPA-CKD研究因在慢性肾脏病患者中的压倒性疗效而计划提前终止

2020-04-03

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL 2020：乙型肝炎新药研发进展

2020-03-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2020 APAGE/APLAR/APSDE/APSH/APSN/PoA联合建议：高血压、心血管、肾脏或胃肠道共病患者应用非甾体类抗炎药治疗

2020-01-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

改良Sauve－Kapandji手术治疗陈旧性下尺桡关节脱位1例

2020-01-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗

2019-12-30

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：Niraparib一线治疗晚期卵巢癌

2019-12-21

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标

2019-12-06

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：达格列净在射血分数降低心衰患者的疗效（DAPA-HF研究）

2019-11-23

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

全球SGLT2i非糖尿病人群数据震撼发布丨葛均波院士、江晨恩教授两大牵头研究者解读DAPA-HF新证据

2019-11-21

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

AHA 2019｜LBS.01 首发四个临床研究：DAPA-HF、ORION-10、COLCOT、 BETonMACE

2019-11-19

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗

2019-10-25

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2019-10-06

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

每周一次的somapacitan治疗生长激素缺乏症儿童，效果与每日一次的生长激素相当

2019-09-25

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点

2019-09-06

科室
- - 订阅+
  - 更多科室
工具
服务